文献速递心脏核医学

肥厚型心肌病分子影像:2-[18F]FDG与[13N]NH3探索性研究

Molecular imaging in hypertrophic cardiomyopathy: an exploratory study with 2-[18F]FDG and [13N]NH3.
PubMed 文献 · EJNMMI Res · 2025-02-28

本研究用PET-CT的[13N]NH3灌注与2-[18F]FDG代谢显像评估30例非梗阻性肥厚型心肌病患者,发现53%患者存在FDG摄取增高,炎症模式与瘢痕模式均与肥厚程度、左房容积、NT-proBNP及猝死风险评分相关。

要点

  • 30例非梗阻性肥厚型心肌病患者中53%存在2-[18F]FDG摄取增高,平均靶本比1.4±0.5。
  • 炎症模式累及左心室11.8±17.2%,与最大室壁厚度、左房容积、NT-proBNP相关。
  • 瘢痕模式累及左心室10.3±10.2%,与猝死风险评分相关(rho=0.38,p=0.04)。

核心结论

  • 在非梗阻性肥厚型心肌病患者中,PET-CT可提供心肌代谢与纤维化的信息,这些信息与心肌肥厚、左心室功能不全及猝死风险密切相关。

研究设计与样本

  • 探索性研究,纳入30例非梗阻性肥厚型心肌病患者,采用PET-CT行[13N]NH3灌注与2-[18F]FDG代谢显像。

主要发现

  • 53%的患者检出2-[18F]FDG摄取增高(靶本比TBR≥1.1),平均TBR为1.4±0.5。
  • 炎症模式累及左心室的11.8±17.2%,与最大室壁厚度(rho=0.49,p=0.009)、左房容积(rho=0.39,p=0.04)及NT-proBNP水平(rho=0.63,p=0.003)相关。
  • 左心室内最大TBR与最大室壁厚度(rho=0.53,p=0.004)、NT-proBNP(rho=0.70,p=0.0008)及猝死风险评分(rho=0.38,p=0.04)相关。
  • 瘢痕模式累及左心室的10.3±10.2%,与猝死风险评分相关(rho=0.38,p=0.04)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertrophic Cardiomyopathy (HCM), a genetic disorder with diverse phenotypes, is associated with risks of heart failure and sudden cardiac death. While the condition involves multiple pathological pathways, including myocardial inflammation, increased workload, myocyte disarray, apoptosis, and fibrosis, the role of molecular imaging via PET-CT remains unexplored in this context. This study aimed to investigate the relationship between myocardial metabolism and perfusion using PET-CT in patients with non-obstructive HCM (NOHCM). RESULTS: Myocardial perfusion and metabolism were assessed using PET-CT with [13N]NH3 and 2-[18F]FDG uptake, respectively, in 30 NOHCM patients. Baseline measurements included maximal myocardial wall thickness (MMWT), left atrial volume (LAV), NT-proBNP levels, and the sudden cardiac death (SCD) risk score. Increased 2-[18F]FDG uptake (Target to Background Ratio - TBR ≥ 1.1) was detected in 53% of patients, with an average TBR of 1.4 ± 0.5. The inflammatory pattern involved 11.8 ± 17.2% of the left ventricle (LV) and correlated with MMWT (rho = 0.49, p = 0.009), LAV (rho = 0.39, p = 0.04), and NT-proBNP levels (rho = 0.63, p = 0.003). The maximum TBR within the LV correlated with MMWT (rho = 0.53, p = 0.004), NT-proBNP (rho = 0.70,p = 0.0008), and the SCD risk score (rho = 0.38,p = 0.04). Additionally, the fibrotic (scar) pattern, involving 10.3 ± 10.2% of the LV, correlated with the SCD score (rho = 0.38,p = 0.04). CONCLUSION: In patients with NOHCM, PET-CT imaging provides valuable insights into myocardial metabolism and fibrosis, which are closely associated with myocardial hypertrophy, left ventricular dysfunction, and the risk of sudden cardiac death.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ferreira MJ, Marques-Alves P, Silva R, et al. Molecular imaging in hypertrophic cardiomyopathy: an exploratory study with 2-[18F]FDG and [13N]NH3. EJNMMI Res. 2025. PMID: 40019587. doi:10.1186/s13550-025-01212-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。